Alkermes plc.
ALKS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001520262
In the last 90 days, Alkermes plc. insiders filed 0 open-market purchases and 5 sales; 427 institutions reported holding it in 13F filings for Q2 2026, worth $9.33B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 |
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Cost of revenue | $196.5M | $245.3M | $253.0M | $218.1M | $197.4M |
| Research and development | $324.0M | $245.3M | $270.8M | $393.8M | $406.5M |
| Selling, general and administrative | $701.5M | $645.2M | $689.8M | $605.7M | $561.0M |
| Operating income | $254.0M | $420.6M | $414.1M | -$142.3M | -$29.3M |
| Interest expense | – | – | $23.0M | $13.0M | $11.2M |
| Income tax | $49.8M | $71.6M | -$97.6M | -$9.04M | $8.86M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M | -$48.2M |
| EPS, basic | $1.47 | $2.22 | $2.14 | $-0.97 | – |
| EPS, diluted | $1.43 | $2.17 | $2.10 | $-0.97 | – |
| Weighted shares, basic | 164.7M | 165.4M | 166.2M | 163.5M | – |
| Weighted shares, diluted | 168.7M | 169.2M | 169.7M | 163.5M | – |
| Margins and growth | |||||
| Operating margin | 17.2% | 27.0% | 24.9% | -12.8% | -2.5% |
| Net margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% |
| Revenue growth, year over year | −5.2% | −6.4% | +49.6% | −5.3% | +13.0% |
| Net income growth, year over year | −34.2% | +3.2% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 |
| Cash and equivalents | $388.6M | $291.1M | $457.5M | $292.5M | $337.5M |
| Short-term investments | – | – | – | – | $198.8M |
| Accounts receivable | $334.0M | $384.5M | $332.5M | $288.0M | $313.2M |
| Inventory | $196.6M | $182.9M | $186.4M | $181.4M | $150.3M |
| Total current assets | $1.93B | $1.42B | $1.49B | $1.13B | $1.06B |
| Property, plant and equipment | $221.7M | $227.6M | $226.9M | $325.4M | $341.1M |
| Goodwill | $83.0M | $83.0M | $83.0M | $92.9M | $92.9M |
| Intangible assets | $815.0K | $890.0K | $1.99M | $37.7M | $74.0M |
| Total assets | $2.49B | $2.06B | $2.14B | $1.96B | $2.02B |
| Accounts payable | $108.0M | $45.6M | $65.6M | $32.8M | $55.7M |
| Short-term debt | – | – | $3.00M | $3.00M | $3.00M |
| Total current liabilities | $543.4M | $465.2M | $520.2M | $497.7M | $471.3M |
| Long-term debt | – | – | $287.7M | $290.3M | $292.8M |
| Total liabilities | $667.7M | $590.6M | $933.5M | $920.2M | $911.9M |
| Shareholders' equity | $1.82B | $1.46B | $1.20B | $1.04B | $1.11B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 16, 2022 |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M | $101.7M |
| Capital expenditures | $40.4M | $33.5M | $48.0M | $38.3M | $28.0M |
| Free cash flow | $480.3M | $405.6M | $353.3M | -$17.2M | $73.7M |
| Depreciation and amortization | $27.2M | $28.5M | $74.9M | $77.9M | $78.7M |
| Stock-based compensation | $98.7M | $96.6M | $100.9M | $94.3M | $87.6M |
| Share buybacks | – | $200.3M | – | – | – |
| Investing cash flow | $295.5M | -$111.3M | $53.4M | -$64.5M | -$66.2M |
| Financing cash flow | $12.4M | -$494.1M | -$289.7M | -$1.57M | $29.1M |
| Net change in cash | $828.6M | -$166.3M | $165.0M | -$45.1M | $64.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.7% | 6.2% | 6.1% | 8.5% | 7.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 168.0M | +1.8% | SEC |
| Jul 23, 2026 | 167.8M | +1.6% | SEC |
| Apr 30, 2026 | 166.7M | +1.1% | SEC |
| Feb 20, 2026 | 166.6M | +2.5% | SEC |
| Oct 24, 2025 | 165.1M | +2.0% | SEC |
| Jul 25, 2025 | 165.1M | +0.2% | SEC |
| Apr 25, 2025 | 164.9M | −2.6% | SEC |
| Feb 7, 2025 | 162.6M | −2.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.